- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Cell bank.
Displaying page 1 of 3.
EudraCT Number: 2005-000615-99 | Sponsor Protocol Number: 00465 | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Freiburger ZNS-NHL Studie Therapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation | |||||||||||||
Medical condition: primary Non-Hodgkin Lymphoma of the Central Nervous System (PCNSL), histologically confirmed Age: 18 - 65 years | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001022-22 | Sponsor Protocol Number: COV-2-STs | Start Date*: 2021-05-14 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients | ||
Medical condition: COVID-19 high-risk patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003665-10 | Sponsor Protocol Number: RBH2017/001 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | |||||||||||||
Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors | |||||||||||||
Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007694-23 | Sponsor Protocol Number: 593 | Start Date*: 2008-07-28 |
Sponsor Name:Forschergruppe Diabetes e. V. | ||
Full Title: Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children with Type 1 Diabetes - A Pilot Study | ||
Medical condition: Type 1 Diabetes | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000857-11 | Sponsor Protocol Number: 345-449 | Start Date*: 2016-05-27 |
Sponsor Name:Bank of Cyprus Oncology Centre | ||
Full Title: A Phase II study of Switch Maintenance Pembrolizumab in patients with Non Small Cell Lung Cancer (NSCLC) who do not progress after First Line Platinum Doublet Chemotherapy | ||
Medical condition: Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CY (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002997-31 | Sponsor Protocol Number: SCH/05/015 | Start Date*: 2006-08-10 |
Sponsor Name:Sheffield Children's NHS Trust | ||
Full Title: A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. | ||
Medical condition: Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. E... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006756-22 | Sponsor Protocol Number: VVS-2.1 | Start Date*: 2009-07-09 |
Sponsor Name:Neocutis | ||
Full Title: VVS study: the efficacy and safety of Bio-restorative Skin Cream in the local treatment of vulvar vestibulitis syndrome (VVS) compared with placebo. | ||
Medical condition: Vulvar vestibulitis syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003884-25 | Sponsor Protocol Number: 4202-HEM-301 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Forma Therapeutics, Inc. | |||||||||||||
Full Title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease | |||||||||||||
Medical condition: sickle cell disease (SCD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Temporarily Halted) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011445-13 | Sponsor Protocol Number: IJB-BGDO-2009-001 | Start Date*: 2009-11-26 |
Sponsor Name:Institut Jules Bordet-Université Libre de Bruxelles | ||
Full Title: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer | ||
Medical condition: Stage III colon adenocarcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000896-17 | Sponsor Protocol Number: SBP-9200-HBV-206 | Start Date*: 2019-05-20 |
Sponsor Name:Spring Bank Pharmaceuticals, Inc. | ||
Full Title: A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AN... | ||
Medical condition: Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows: Cohort 1 Subjects who have been on NUC t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004063-52 | Sponsor Protocol Number: RV-MM-PI-0694 | Start Date*: 2013-03-21 | |||||||||||
Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS | |||||||||||||
Full Title: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST VGPR AFTER INDUCTION THERAPY: MINIMAL RESIDUAL DISEASE MONITORING | |||||||||||||
Medical condition: Patients with Multiple Myeloma in maintenance treatment with Lenalidomide | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002602-12 | Sponsor Protocol Number: 16/SEP/6613E | Start Date*: 2018-01-12 |
Sponsor Name:Cardiff and Vale University Health Board | ||
Full Title: Improving Transplant Opportunities for Patients who are Sensitised (ITOPS) – a feasibility, randomised, controlled phase III trial | ||
Medical condition: Highly Sensitised Patients(patients with high levels of human leucocyte antigen specific antibodies) awaiting renal transplantation.These patients are difficult to match to a compatible donor and t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002007-15 | Sponsor Protocol Number: AXL-003 | Start Date*: 2011-10-12 | ||||||||||||||||
Sponsor Name:Axelar AB | ||||||||||||||||||
Full Title: Phase II, randomized, open-label study of the IGF-1R inhibitor AXL1717 compared to docetaxel in patients with previously treated, locally advanced, or metastatic squamous cell carcinoma or adenocar... | ||||||||||||||||||
Medical condition: Non-small-cell lung cancer previously treated | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004039-30 | Sponsor Protocol Number: MCL5(MARiT) | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:PLymouth Hospitals NHS Trust | |||||||||||||
Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000260-17 | Sponsor Protocol Number: PCV-Dip | Start Date*: 2014-03-18 | ||||||||||||||||
Sponsor Name:Universität Innsbruck, Institut für Biomedizinische Alternsforschung | ||||||||||||||||||
Full Title: Pneumococcal conjugate vaccines in the elderly: The role of carrier-specific T cells | ||||||||||||||||||
Medical condition: This study investigates humoral immune responses to pneumococcal conjugate vaccine as well as humoral and T cell responses to the diphtheria-component of the Tdap vaccine. Healthy adults over 50 ye... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007659-15 | Sponsor Protocol Number: NC-07-03 | Start Date*: 2008-04-22 | ||||||||||||||||||||||||||
Sponsor Name:Lumavita AG | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Investigate the Efficacy, Safety, and Tolerability of 3 doses of SPK 0602 (pentamycin) Vaginal Tablets vs Placebo (veh... | ||||||||||||||||||||||||||||
Medical condition: Symptomatic Vaginitis due to Bacterial Vaginosis, Candidiasis or Trichomoniasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: EE (Completed) DE (Completed) HU (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001784-36 | Sponsor Protocol Number: PAED-201601 | Start Date*: 2019-08-12 |
Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | ||
Full Title: Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin | ||
Medical condition: Extracranial germ cell tumours of any malignant histology, primary site and stage | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003226-27 | Sponsor Protocol Number: RG_10-151 | Start Date*: 2012-11-02 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma | |||||||||||||
Medical condition: Metastatic Merkel Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002640-23 | Sponsor Protocol Number: APHP200003 | Start Date*: 2020-12-14 |
Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | ||
Full Title: Effect of increased oxytocin doses on the mode of delivery in obese primiparous women with spontaneous labour. A double-blind, randomised, controlled trial | ||
Medical condition: To compare the rates of caesarean section in obese patients with spontaneous labour between two oxytocin dosage regimens | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003930-17 | Sponsor Protocol Number: 1407-GUCG | Start Date*: 2015-10-05 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO... | |||||||||||||
Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) SI (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
